Sanofi (SNY) Competitors

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Do institutionals & insiders have more ownership in NVO or SNY?

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has higher earnings & valuation, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$42.12B	N/A	$14.64B	$3.38	20.92
Sanofi	$44.46B	2.67	$6.02B	$2.80	17.29

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.52%	80.94%	24.23%
Sanofi	14.56%	17.15%	9.80%

Do analysts rate NVO or SNY?

Novo Nordisk A/S currently has a consensus price target of $112.00, indicating a potential upside of 58.42%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 27.01%. Given Novo Nordisk A/S's higher probable upside, research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Sanofi	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	3 Strong Buy rating(s)	3.13

Does the MarketBeat Community prefer NVO or SNY?

Novo Nordisk A/S received 382 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.70% of users gave Novo Nordisk A/S an outperform vote while only 60.92% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Novo Nordisk A/S	Outperform Votes 435 61.70%	Underperform Votes 270 38.30%
Sanofi	Outperform Votes 53 60.92%	Underperform Votes 34 39.08%

Is NVO or SNY a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.3%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Sanofi pays out 57.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has more volatility & risk, NVO or SNY?

Novo Nordisk A/S has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Does the media prefer NVO or SNY?

In the previous week, Novo Nordisk A/S had 33 more articles in the media than Sanofi. MarketBeat recorded 55 mentions for Novo Nordisk A/S and 22 mentions for Sanofi. Sanofi's average media sentiment score of 0.86 beat Novo Nordisk A/S's score of 0.28 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	14 Very Positive mention(s)	1 Positive mention(s)	23 Neutral mention(s)	14 Negative mention(s)	3 Very Negative mention(s)	Neutral
Sanofi	11 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.